AU2002211366A1 - Human anti-cd40 antibodies - Google Patents

Human anti-cd40 antibodies

Info

Publication number: AU2002211366A1
Authority: AU; Australia
Prior art keywords: antigen; antibody; cell; binding fragment; antagonist
Prior art date: 2000-10-02
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2002211366A

Other languages

English (en)

Inventor

Keting Chu

John J. Donnelly

Changyu Wang

Corrine Yoshihara

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Novartis Vaccines and Diagnostics Inc

Original Assignee

Chiron Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-10-02

Filing date

2001-10-02

Publication date

2002-04-15

2001-10-02 Application filed by Chiron Corp filed Critical Chiron Corp

2002-04-15 Publication of AU2002211366A1 publication Critical patent/AU2002211366A1/en

Status Abandoned legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Hematology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Rheumatology (AREA)
Oncology (AREA)
Diabetes (AREA)
Neurology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Transplantation (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

AU2002211366A 2000-10-02 2001-10-02 Human anti-cd40 antibodies Abandoned AU2002211366A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US23755600P	2000-10-02	2000-10-02
US60/237,556		2000-10-02
PCT/US2001/030857 WO2002028904A2 (en)	2000-10-02	2001-10-02	Human anti-cd40 antibodies

Publications (1)

Publication Number	Publication Date
AU2002211366A1 true AU2002211366A1 (en)	2002-04-15

Family

ID=22894238

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
AU2002211366A Abandoned AU2002211366A1 (en)	2000-10-02	2001-10-02	Human anti-cd40 antibodies
AU2001296545A Abandoned AU2001296545A1 (en)	2000-10-02	2001-10-02	Methods of therapy for b-cell malignancies
AU2001296507A Abandoned AU2001296507A1 (en)	2000-10-02	2001-10-02	Human anti-cd40 antibodies
AU2001296547A Abandoned AU2001296547A1 (en)	2000-10-02	2001-10-02	Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies

Family Applications After (3)

Application Number	Title	Priority Date	Filing Date
AU2001296545A Abandoned AU2001296545A1 (en)	2000-10-02	2001-10-02	Methods of therapy for b-cell malignancies
AU2001296507A Abandoned AU2001296507A1 (en)	2000-10-02	2001-10-02	Human anti-cd40 antibodies
AU2001296547A Abandoned AU2001296547A1 (en)	2000-10-02	2001-10-02	Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies

Country Status (10)

Country	Link
US (5)	US7288252B2 (es)
EP (3)	EP1322383B9 (es)
JP (6)	JP4202127B2 (es)
AT (3)	ATE541860T1 (es)
AU (4)	AU2002211366A1 (es)
CA (2)	CA2424749A1 (es)
DE (2)	DE60119945T2 (es)
ES (1)	ES2357051T3 (es)
PT (1)	PT1326896E (es)
WO (4)	WO2002028481A2 (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
ES2357051T3 (es)	2000-10-02	2011-04-15	Novartis Vaccines And Diagnostics, Inc.	Anticuerpos humanos anti-cd40.
US7507724B2 (en)	2001-01-16	2009-03-24	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
US7906492B2 (en)	2001-01-16	2011-03-15	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
EP2009027B1 (en)	2001-04-27	2014-05-21	Kyowa Hakko Kirin Co., Ltd.	Anti-CD40 monoclonal antibody
US8277810B2 (en)	2003-11-04	2012-10-02	Novartis Vaccines & Diagnostics, Inc.	Antagonist anti-CD40 antibodies
CA2544368C (en) *	2003-11-04	2014-04-01	Chiron Corporation	Methods of therapy for b cell-related cancers
US20070110754A1 (en) *	2003-11-04	2007-05-17	Chiron Corporation	Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
EP1684805B8 (en) *	2003-11-04	2010-08-25	Novartis Vaccines and Diagnostics, Inc.	Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP2248830A1 (en) *	2003-11-04	2010-11-10	Novartis Vaccines and Diagnostics, Inc.	Use of antagonist anti-CD40 antibodies for treatment of autoimmune and inflammatory diseases and organ transplant rejection
DE602004028643D1 (de) *	2003-11-04	2010-09-23	Novartis Vaccines & Diagnostic	Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
US20050136055A1 (en) *	2003-12-22	2005-06-23	Pfizer Inc	CD40 antibody formulation and methods
US20070292439A1 (en) *	2004-04-27	2007-12-20	Novartis Vaccines And Diagnostics, Inc.	Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
AU2006235695B2 (en)	2005-04-09	2011-10-13	Fusion Antibodies Limited	Cathepsin S antibody
AU2006247134B2 (en) *	2005-05-18	2012-05-10	Novartis Ag	Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
AU2006247067B2 (en) *	2005-05-18	2012-06-07	Novartis Ag	Methods for diagnosis and treatment of proliferative disorders mediated by CD40 signaling
CN101325970B (zh) *	2005-11-01	2013-08-14	诺华有限公司	抗cd40抗体的应用
US20090053221A1 (en) *	2006-01-17	2009-02-26	Cheung Nai-Kong V	Immune response enhancing glucan
US8323644B2 (en) *	2006-01-17	2012-12-04	Sloan-Kettering Institute For Cancer Research	Therapy-enhancing glucan
GEP20125628B (en)	2006-04-21	2012-09-10	Novartis Ag	Pharmaceutical compositions containing antagonist anti-cd40 antibody
WO2007130493A2 (en)	2006-05-03	2007-11-15	Regents Of The University Of Colorado	Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) *	2006-09-07	2009-03-19	University Of Southhampton	Human therapies using chimeric agonistic anti-human cd40 antibody
EP2176298B1 (en)	2007-05-30	2017-11-15	Xencor, Inc.	Methods and compositions for inhibiting cd32b expressing cells
MX2010005099A (es) *	2007-11-09	2010-05-27	Novartis Ag	Usos de anticuerpos anti-cd40.
AU2009206506B2 (en)	2008-01-23	2013-01-10	Xencor, Inc.	Optimized CD40 antibodies and methods of using the same
PT2406286T (pt) *	2009-03-10	2016-08-19	Baylor Res Inst	Anticorpos anti-cd40 e seus usos
JP5883653B2 (ja)	2009-03-10	2016-03-15	ベイラーリサーチインスティテュートＢａｙｌｏｒＲｅｓｅａｒｃｈＩｎｓｔｉｔｕｔｅ	抗原提示細胞ターゲティング抗ウイルスワクチン
DK3138854T3 (da)	2009-03-10	2022-04-11	Baylor Res Institute	Antistoffer mod CD40
WO2011109280A1 (en)	2010-03-05	2011-09-09	Lerner Research Institute	Methods and compositions to treat immune-mediated disorders
EP3372617B1 (en)	2010-04-02	2024-07-24	Amunix Pharmaceuticals, Inc.	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
AR083847A1 (es)	2010-11-15	2013-03-27	Novartis Ag	Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012075111A1 (en)	2010-11-30	2012-06-07	Novartis Ag	Uses of anti-cd40 antibodies in combination therapy for b cell-related cancers
DK3556774T3 (da)	2011-03-11	2024-03-25	Univ Emory	Anti-CD40-antistoffer og anvendelser deraf
TW201300418A (zh)	2011-03-25	2013-01-01	Baylor Res Inst	用於抗ｃ型肝炎病毒免疫之組合物及方法
EA030851B1 (ru) *	2011-04-21	2018-10-31	Бристол-Майерс Сквибб Компани	Полипептиды антитела, которые антагонизируют cd40
CN104105707B (zh)	2011-11-17	2020-03-06	G·容	医疗用途的双特异性抗体
JP2016011258A (ja) *	2012-10-26	2016-01-21	株式会社ペルセウスプロテオミクス	抗ヒトｃｄ４０モノクローナル抗体及びその利用
JP6475631B2 (ja)	2012-11-19	2019-02-27	バリオファルム・アクチェンゲゼルシャフト	Ｃｄ２０およびｃｄ９５に結合する組換え二重特異性抗体
CA2936833A1 (en)	2014-01-13	2015-07-16	Baylor Research Institute	Novel vaccines against hpv and hpv-related diseases
US10435475B2 (en)	2014-03-07	2019-10-08	Bristol-Myers Squibb Company	Method of using antibody polypeptides that antagonize CD40 to treat IBD
CN107073118B (zh)	2014-10-29	2022-03-01	西雅图基因公司	非岩藻糖基化抗cd40抗体的剂量和给药
CN113699116A (zh)	2014-12-10	2021-11-26	明尼苏达大学董事会	用于治疗疾病的遗传修饰的细胞、组织和器官
DK3303395T3 (da)	2015-05-29	2020-01-27	Abbvie Inc	Anti-cd40-antistoffer og anvendelser deraf
AU2016315873B2 (en)	2015-09-04	2022-08-18	Primatope Therapeutics Inc.	Humanized anti-CD40 antibodies and uses thereof
BR112018006251A2 (pt) *	2015-09-30	2018-10-16	Janssen Biotech Inc	anticorpos antagonistas que se ligam especificamente a cd40 humano e métodos de uso
EP4371570A3 (en)	2016-06-08	2024-07-17	Xencor, Inc.	Treatment of igg4-related diseases with anti-cd19 antibodies crossbinding to cd32b
CA3026474A1 (en)	2016-06-20	2017-12-28	Kymab Limited	Anti-pd-l1 and il-2 cytokines
CA3030636A1 (en)	2016-07-14	2018-01-18	Genmab A/S	Multispecific antibodies against cd40 and cd137
EP4252629A3 (en)	2016-12-07	2023-12-27	Biora Therapeutics, Inc.	Gastrointestinal tract detection methods, devices and systems
WO2018183929A1 (en)	2017-03-30	2018-10-04	Progenity Inc.	Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
JP7257971B6 (ja)	2017-06-01	2023-07-24	江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司	抗ｃｄ４０抗体、その抗原結合フラグメント、およびその医学的使用
CN108503708B (zh) *	2017-09-01	2021-07-30	北京智仁美博生物科技有限公司	抗人cd47抗体及其用途
US10610585B2 (en)	2017-09-26	2020-04-07	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Methods and compositions for treating and preventing HIV
CN112638375A (zh)	2018-06-15	2021-04-09	旗舰创业创新五公司	通过后细胞信号传导因子的调节来增加免疫活性
US20230009902A1 (en)	2018-06-20	2023-01-12	Progenity, Inc.	Treatment of a disease or condition in a tissue orginating from the endoderm
WO2019246312A1 (en)	2018-06-20	2019-12-26	Progenity, Inc.	Treatment of a disease of the gastrointestinal tract with an immunomodulator
EP3860653A1 (en)	2018-10-05	2021-08-11	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and systems for controlling the agonistic properties of antibody variable domains by light
JP7482866B2 (ja)	2018-11-19	2024-05-14	ビオラ・セラピューティクス・インコーポレイテッド	生物学的治療薬による疾患処置方法およびデバイス
BR112021010414A2 (pt)	2018-11-30	2021-09-08	Jiangsu Hengrui Medicine Co., Ltd.	Composição farmacêutica compreendendo um anticorpo cd40, método para preparar uma preparação liofilizada, preparação liofilizada, uso das mesmas e produto que compreende um recipiente contendo as mesmas
KR20210099027A (ko)	2018-11-30	2021-08-11	지앙수 헨그루이 메디슨 컴퍼니 리미티드	항-cd40 항체, 이의 항원-결합 단편 및 약학적 용도
NL2022494B1 (en) *	2019-02-01	2020-08-19	Lava Therapeutics B V	Novel CD40-binding antibodies
AU2020216250A1 (en) *	2019-02-01	2021-08-26	LAVA Therapeutics N.V.	Novel CD40-binding antibodies
MA55805A (fr)	2019-05-03	2022-03-09	Flagship Pioneering Innovations V Inc	Métodes de modulation de l'activité immunitaire
CN115666704A (zh)	2019-12-13	2023-01-31	比奥拉治疗股份有限公司	用于将治疗剂递送至胃肠道的可摄取装置
EP4076434A1 (en)	2019-12-17	2022-10-26	Flagship Pioneering Innovations V, Inc.	Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
WO2022006179A1 (en)	2020-06-29	2022-01-06	Flagship Pioneering Innovations V, Inc.	Viruses engineered to promote thanotransmission and their use in treating cancer
MX2023008949A (es)	2021-01-28	2023-10-23	Regeneron Pharma	Composiciones y metodos para tratar el sindrome de liberacion de citocinas.
IL305681A (en)	2021-03-09	2023-11-01	Genmab As	Multispecific binding agents against CD40 and CD137 in therapy
EP4313109A1 (en)	2021-03-31	2024-02-07	Flagship Pioneering Innovations V, Inc.	Thanotransmission polypeptides and their use in treating cancer
JP2024525475A (ja)	2021-06-29	2024-07-12	フラグシップパイオニアリングイノベーションズブイ，インコーポレーテッド	タノトランスミッションを促進するように操作された免疫細胞及びその使用
CA3225254A1 (en)	2021-07-13	2023-01-19	BioNTech SE	Multispecific binding agents against cd40 and cd137 in combination therapy for cancer
EP4393937A1 (en)	2021-08-26	2024-07-03	Duality Biologics (Suzhou) Co., Ltd.	Steroid compound and conjugate thereof
WO2023198851A1 (en)	2022-04-14	2023-10-19	Institut National de la Santé et de la Recherche Médicale	Methods for controlling the tumor cell killing by light
US20240174732A1 (en)	2022-10-05	2024-05-30	Flagship Pioneering Innovations V, Inc.	Nucleic acid molecules encoding trif and additional polypeptides and their use in treating cancer
WO2024115725A1 (en)	2022-12-01	2024-06-06	BioNTech SE	Multispecific antibody against cd40 and cd137 in combination therapy with anti-pd1 ab and chemotherapy
US20240269251A1 (en)	2023-01-09	2024-08-15	Flagship Pioneering Innovations V, Inc.	Genetic switches and their use in treating cancer

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US142358A (en) *		1873-09-02		Improvement in the purification of illuminating-gas
US59427A (en) *		1866-11-06		Improvement in fences
US4355023A (en)	1980-09-30	1982-10-19	The Massachusetts General Hospital	Antibody fragment compositions and process
NZ201918A (en)	1981-09-18	1987-04-30	Genentech Inc	N-terminal methionyl analogues of bovine growth hormone
US4689299A (en)	1982-09-30	1987-08-25	University Of Rochester	Human monoclonal antibodies against bacterial toxins
EP0138854B1 (en)	1983-03-08	1992-11-04	Chiron Mimotopes Pty. Ltd.	Antigenically active amino acid sequences
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
NZ212051A (en)	1984-05-18	1988-10-28	Univ Australian	Immune response suppression; certain epipolythio- dioxopiperazine derivatives and their preparation
US5068223A (en)	1985-09-09	1991-11-26	Board Of Regents, University Of Texas System	Hydrophobic peptide esters and amides
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US5182368A (en)	1986-06-13	1993-01-26	Ledbetter Jeffrey A	Ligands and methods for augmenting B-cell proliferation
US4923872A (en)	1986-08-26	1990-05-08	Warner-Lambert Co.	Analogues of pyrrolo[3,2d]pyrimidin-4-ones
US4831175A (en)	1986-09-05	1989-05-16	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
ES2051726T3 (es) *	1987-01-17	1994-07-01	Asta Medica Ag	Procedimiento para preparar productos inyectables que contienen azelastin y teofilina o azelastin y beta-mimeticos.
IL162181A (en)	1988-12-28	2006-04-10	Pdl Biopharma Inc	A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5100899A (en)	1989-06-06	1992-03-31	Roy Calne	Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
EP0434879A1 (en)	1989-12-14	1991-07-03	Schering-Plough	Method of making factor dependent human B cell lines
CA2086325C (en)	1990-07-02	2010-10-05	Peter S. Linsley	Ligand for cd28 receptor on b cells and methods
WO1993008207A1 (en)	1991-10-25	1993-04-29	Immunex Corporation	Novel cytokine
ATE249840T1 (de)	1991-12-13	2003-10-15	Xoma Corp	Verfahren und materialien zur herstellung von modifizierten variablen antikörperdomänen und ihre therapeutische verwendung
CA2089229C (en)	1992-02-14	2010-04-13	Alejandro A. Aruffo	Cd40cr receptor and ligands therefor
US5684129A (en)	1992-07-07	1997-11-04	Fish; Eleanor N.	Interferon receptor binding peptides
DK0945465T3 (da) *	1992-07-09	2007-01-15	Novartis Vaccines & Diagnostic	Antagonistiske monoklonale antistoffer mod humant CD40
US5874082A (en)	1992-07-09	1999-02-23	Chiron Corporation	Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en)	1992-07-09	1995-03-14	Cetus Oncology Corporation	Method for generation of antibodies to cell surface molecules
WO1994004570A1 (en)	1992-08-21	1994-03-03	Schering Corporation	Cd40 ligand, anti cd40 antibodies, and soluble cd40
DE614989T1 (de)	1993-02-17	1995-09-28	Morphosys Proteinoptimierung	Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US5595721A (en)	1993-09-16	1997-01-21	Coulter Pharmaceutical, Inc.	Radioimmunotherapy of lymphoma using anti-CD20
AU686230B2 (en)	1993-10-01	1998-02-05	Immunex Corporation	Antibodies to CD40
WO1995017202A1 (en)	1993-12-23	1995-06-29	Immunex Corporation	Method of preventing or treating disease characterized by neoplastic cells expressing cd40
EP0823941A4 (en) *	1995-04-28	2001-09-19	Abgenix Inc	HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US20020102208A1 (en)	1999-03-01	2002-08-01	Paul Chinn	Radiolabeling kit and binding assay
MY133346A (en)	1999-03-01	2007-11-30	Biogen Inc	Kit for radiolabeling ligands with yttrium-90
AR023482A1 (es)	1999-04-16	2002-09-04	Hoffmann La Roche	Acidos nucleicos que codifican polipeptidos quimericos cd40/cd4ol, metodos para su produccion y usos de los mismos
US6946129B1 (en)	1999-06-08	2005-09-20	Seattle Genetics, Inc.	Recombinant anti-CD40 antibody and uses thereof
EP1221973B1 (en)	1999-10-04	2007-05-30	Novartis Vaccines and Diagnostics, Inc.	CD40 antagonist for treating psoriasis
US20020028178A1 (en) *	2000-07-12	2002-03-07	Nabil Hanna	Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
AU1590201A (en)	1999-11-09	2001-06-06	Chiron Corporation	Compositions and methods for treating autoimmune diseases and transplant rejections
US7063845B2 (en)	2000-04-28	2006-06-20	Gemini Science, Inc.	Human anti-CD40 antibodies
US20030059427A1 (en)	2000-04-28	2003-03-27	Force Walker R.	Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) *	2000-04-28	2001-11-08	La Jolla Institute For Allergy And Immunology	Human anti-cd40 antibodies and methods of making and using same
ES2357051T3 (es)	2000-10-02	2011-04-15	Novartis Vaccines And Diagnostics, Inc.	Anticuerpos humanos anti-cd40.

2001
- 2001-10-02 ES ES01979395T patent/ES2357051T3/es not_active Expired - Lifetime
- 2001-10-02 US US10/380,223 patent/US7288252B2/en not_active Expired - Fee Related
- 2001-10-02 AT AT06005656T patent/ATE541860T1/de active
- 2001-10-02 PT PT01979395T patent/PT1326896E/pt unknown
- 2001-10-02 EP EP01977428A patent/EP1322383B9/en not_active Expired - Lifetime
- 2001-10-02 AT AT01979395T patent/ATE489403T1/de active
- 2001-10-02 JP JP2002532304A patent/JP4202127B2/ja not_active Expired - Fee Related
- 2001-10-02 AU AU2002211366A patent/AU2002211366A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030963 patent/WO2002028481A2/en active IP Right Grant
- 2001-10-02 WO PCT/US2001/030859 patent/WO2002028905A2/en active Application Filing
- 2001-10-02 AU AU2001296545A patent/AU2001296545A1/en not_active Abandoned
- 2001-10-02 EP EP01979395A patent/EP1326896B1/en not_active Expired - Lifetime
- 2001-10-02 AU AU2001296507A patent/AU2001296507A1/en not_active Abandoned
- 2001-10-02 AU AU2001296547A patent/AU2001296547A1/en not_active Abandoned
- 2001-10-02 DE DE60119945T patent/DE60119945T2/de not_active Expired - Lifetime
- 2001-10-02 DE DE60143535T patent/DE60143535D1/de not_active Expired - Lifetime
- 2001-10-02 JP JP2002532486A patent/JP4271440B2/ja not_active Expired - Lifetime
- 2001-10-02 CA CA002424749A patent/CA2424749A1/en not_active Abandoned
- 2001-10-02 WO PCT/US2001/030857 patent/WO2002028904A2/en active Application Filing
- 2001-10-02 WO PCT/US2001/030961 patent/WO2002028480A2/en active Application Filing
- 2001-10-02 AT AT01977428T patent/ATE327004T1/de not_active IP Right Cessation
- 2001-10-02 CA CA002424296A patent/CA2424296A1/en not_active Abandoned
- 2001-10-02 EP EP06005656A patent/EP1717251B1/en not_active Expired - Lifetime
2007
- 2007-08-31 US US11/849,107 patent/US7445780B2/en not_active Expired - Fee Related
- 2007-11-19 JP JP2007299859A patent/JP2008156339A/ja active Pending
- 2007-11-26 JP JP2007305086A patent/JP2008074870A/ja active Pending
2008
- 2008-08-28 JP JP2008220544A patent/JP4838831B2/ja not_active Expired - Fee Related
- 2008-10-06 US US12/246,029 patent/US7611708B2/en not_active Expired - Fee Related
2009
- 2009-06-16 JP JP2009143746A patent/JP2009201523A/ja active Pending
- 2009-09-28 US US12/568,373 patent/US7820170B2/en not_active Expired - Fee Related
2010
- 2010-09-27 US US12/891,415 patent/US8088383B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP1326896B1 (en)	2010-11-24
PT1326896E (pt)	2011-03-03
JP2004510752A (ja)	2004-04-08
JP2009019046A (ja)	2009-01-29
WO2002028480A3 (en)	2002-07-11
CA2424296A1 (en)	2002-04-11
WO2002028905A2 (en)	2002-04-11
US8088383B2 (en)	2012-01-03
US7445780B2 (en)	2008-11-04
WO2002028904A2 (en)	2002-04-11
EP1326896A2 (en)	2003-07-16
CA2424749A1 (en)	2002-04-11
JP4838831B2 (ja)	2011-12-14
JP2008074870A (ja)	2008-04-03
US7820170B2 (en)	2010-10-26
EP1322383A2 (en)	2003-07-02
EP1717251A2 (en)	2006-11-02
ATE489403T1 (de)	2010-12-15
JP4271440B2 (ja)	2009-06-03
WO2002028481A3 (en)	2003-03-06
WO2002028905A3 (en)	2002-06-20
JP4202127B2 (ja)	2008-12-24
US20080075727A1 (en)	2008-03-27
AU2001296545A1 (en)	2002-04-15
WO2002028904A3 (en)	2003-02-06
US7288252B2 (en)	2007-10-30
US20100172912A1 (en)	2010-07-08
EP1322383B9 (en)	2006-09-06
DE60119945D1 (de)	2006-06-29
JP2008156339A (ja)	2008-07-10
US20110033456A1 (en)	2011-02-10
US20090081242A1 (en)	2009-03-26
DE60143535D1 (de)	2011-01-05
EP1717251A3 (en)	2007-11-07
EP1717251B1 (en)	2012-01-18
WO2002028480A2 (en)	2002-04-11
AU2001296547A1 (en)	2002-04-15
US20040109857A1 (en)	2004-06-10
AU2001296507A1 (en)	2002-04-15
JP2004517611A (ja)	2004-06-17
WO2002028481A2 (en)	2002-04-11
WO2002028481A9 (en)	2003-07-03
EP1322383B1 (en)	2006-05-24
ES2357051T3 (es)	2011-04-15
ATE541860T1 (de)	2012-02-15
ATE327004T1 (de)	2006-06-15
DE60119945T2 (de)	2007-01-18
JP2009201523A (ja)	2009-09-10
US7611708B2 (en)	2009-11-03

Publication	Publication Date	Title
AU2001296507A1 (en)	2002-04-15	Human anti-cd40 antibodies
EP1684805B8 (en)	2010-08-25	Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
WO2005044854A3 (en)	2005-08-11	Antagonist anti-cd40 monoclonal antibodies and methods for their use
WO2005044304A3 (en)	2005-08-25	Use of antagonist anti-cd40 antibodies for treatment of chronic lymphocytic leukemia
AU2190997A (en)	1997-09-10	Humanized anti-cd40 monoclonal antibodies and fragments capable of blocking b cell activation
HK1093690A1 (en)	2007-03-09	Methods of therapy for solid tumors expressing the cd40 cell-surface antigen
HK1106736A1 (en)	2008-03-20	Combination therapy comprising anti-cd20 and anti-cd40 antibodies for the treatment of b cell-related cancers
NZ515992A (en)	2004-01-30	Use of antibodies against CD20 for the treatment of the graft versus host disease
WO2000020864A8 (en)	2001-02-08	Immunotherapy of b cell involvement in progression of solid, nonlymphoid tumors
NZ596878A (en)	2013-07-26	Methods of administering anti-tnfalpha antibodies
NZ592039A (en)	2013-03-28	Combination therapy for the treatment of ocular neovascular disorders
NZ515464A (en)	2004-02-27	Treatment of fibrosis by antagonism of IL-13 and IL-13 receptor chains
AU3386100A (en)	2000-09-21	Anti-tnfalpha antibodies in therapy of asthma
TR200103432T2 (tr)	2002-10-21	Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
EP2641611A3 (en)	2013-12-18	Combination therapy
WO2004019991A3 (en)	2004-04-15	Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
NZ329403A (en)	2000-09-29	Treatment of B-cell lymphomas using a CD40 binding protein that inhibits the binding of CD40 to CD40L
CY1114654T1 (el)	2016-12-14	Anti-cd40 μονοκλωνικα αντισωματα ανταγωνιστες και μεθοδοι για την χρηση αυτων
MX9603999A (es)	1997-12-31	Tratamiento de nefropatia diabetica con valsartan.